Monday, October 31, 2016

The Softer Machine: How Robots Are Filling Important Gaps in Global Healthcare and Biotech R&D

If you blink you will most likely miss some major design, invention or discovery in the robotics industry. The future is definitely here, and robots are becoming an inseparable (if sometimes unseen) part of our everyday lives, whether it’s in defense, manufacturing, biotechnology, caring directly for us, or used in and on our bodies.

The Co-bots are coming, and they're here to help
Robotics is set to be a $226 billion dollar industry by 2021, just 5 years from now. There are no statistics on exactly how much of that industry is healthcare related but there is some scattered research out there. For example, Medgadget tells us that surgical robotics systems will be a $6.4 billion dollar industry by 2020, and the exoskeleton robot market is to reach over $2 billion by 2021. Robotics and Automation News reports that “half of all surgeries in some countries are now done with robots.” Other aspects of healthcare using robotics include nursing and assistance to the elderly and those with disabilities. Biotech manufacturing uses robotics (IFR reports that by 2019, more than 1.4 million new industrial robots will be installed in factories around the world) and even biotech R&D has begun trying them out. The Financial Times reports how GlaxoSmithKline in the UK is using “co-bots to work side by side with scientists at research facilities.”


Robotics Looks to the Deep Sea for Biotech R&D
This past September MedTechPulse compiled a great slideshow “9 Ways Robots Are Getting So Much Better”. I recognized a few of these robots, as they had come out of the Boston/Cambridge biotech cluster – no surprise here. Research institutes such as The Wyss Institute in Cambridge, Massachusetts are creating their own robots, but they're not the kind that will clean your house. Instead, these robots have been created to stretch the limits of what we can accomplish in surgery, internal medicine and tissue engineering.

What Does an Octopus-Inspired Robot Do (And Why Create It)? 
This past summer Harvard University’s Wyss Institute created one of the cutest robots you’ll ever see, in the shape of an octopus. Their inspiration to create a robot using this shape was due to an octopus’ “ability to perform great feats of strength and flexibility, despite lacking an internal skeletal system”. The team at Wyss did a 180 on how robots are thought of (as made of hard components). What a soft robot can do is utilize "fuel" in a very different way. Softness also promises these benefits: “Soft robotic grippers are already being used to handle undersea structures in scientific research. One can easily envision soft robots being used to handle fragile objects such as crops, or even living beings. Internal medicine and wearable devices are also likely areas for future soft robots.” And did I mention that this robot was 3-D Printed?

Rat + Robot = Stingray
Wyss Institute’s Kevin Kit Parker, in his quest to eventually build a human heart, was inspired by the jellyfish and stringrays that he and his daughter saw at the New England Aquarium. Parker thought understanding more about the way they moved could give us a better understanding of the human heart. Parker mimicked the stringrays’ anatomy to create a soft robot (“gold skeleton sandwiched between two silicone layers”) with a difference. This robot incorporated 200,000 heart cells (from rat embryos). The plan was for these cardiac cells to do the work of skeletal muscles (which they did) powered by a virus and optogenetics. In their report, Science magazine joked that the stringray’s speed is ”quite pathetic by real stingray standards” but quoted Princeton engineer Alexander Smits to make a final point “we’re getting to the point where there really is a fusion between biology and engineering”.

Robot Doctors, Robot Nurses and “Carebots”
Nurses at Beth Israel Deaconess Hospital in Boston are using a humanoid robot designed by SoftBank robotics to help them with scheduling - which even for humans is a pretty daunting and complex task. Researchers at MIT showed the robot exactly how nurses were doing the scheduling, which involved complex, highly coordinated actions, and after training the robot succeeded in the tasks 90% of the time. Humber River Hospital in Toronto has taken it several steps further as North America’s first fully digital hospital; SiliconANGLE describes the scene at Humber River: “In the hospital, you will find robots mingling amongst human staff, with robots responsible for mixing the correct dosage of chemotherapy drugs, to transporting meals, medications, and linen”.

The Atlantic reports that doctors as well as nurses are being replaced by robots in countries where doctors are hard to come by. “In Brazil and India, machines are already starting to do primary care, because there’s no labor to do it,” says Robert Kocher, an internist, a veteran of McKinsey consulting, and a former adviser to the Obama administration. “They may be better than doctors. Mathematically, they will follow evidence—and they’re much more likely to be right.”

By 2025, Japan will have a shortage of 1 million caregivers for their aging population; to solve this issue Japanese companies are leading the world in the production of carebots. Emerging tech thought leader Alec Ross described the state of Japan’s carebots industry in a LinkedIn Pulse post earlier this year: “Japan already leads the world in robotics, operating 310,000 of the 1.4 million industrial robots in existence across the world…In 2013, the Japanese government granted $24.6 million to companies focusing on eldercare robotics. Japan’s prominent Ministry of Economy, Trade, and Industry chose 24 companies in May 2013 to receive subsidies covering one-half to two-thirds of the R&D costs for nursing care robots.”

Boston as Robotics Hub
Along with the incredible 3-D printed and bioengineered robots that The Wyss Institute has given us this year, there is evidence that biotech hub Boston is also growing as a robotics hub. Tom Ryden, executive Director of Mass Robotics, describes the current vibe in Boston Business Journal earlier this month: “(Massachusetts robotics companies are) very open in sharing so they want to see all companies grow,” he said. “They realize it’s a ‘rising tide floats all boats’ type of thought…Not not only do we have some of the early companies like iRobot that really started this kind of revolution, but there are so many universities that have robotics programs or are doing robotics research in the Greater Boston area. That makes for a great idea generator, so it just kind of snowballed and built a great community.”

Last year CNBC reported that in Massachusetts: “more than 3,200 people (were) employed in the robotics industry. More than $200 million has been invested in Massachusetts robotics companies since 2008, and annual sales of robotics manufactured in state have topped nearly $2 billion.” The Mass Technology Research Council has an entire report devoted to “The Massachusetts Robotics Revolution” which you can download here.

Interested in hearing more about innovations in the intersection of bioengineering and medicine? Download our report here. And don't forget to follow Biotech Week Boston on Twitter for news on innovation in biotech and medicine. Each year passionate scientists and innovators converge on Boston to share ground breaking data, research and ideas - don't miss our next event in September 2017!




Share this article with your social network, just click below to share now!


Monday, October 24, 2016

3D Bioprinting to Engineer Human Tissue: Wyss Institute's David Kolesky at Biotech Week Boston

The medical 3D printing market is expected to reach $983.2 million by the year 2020. What is the difference between medical and other 3D printing? Well to explain very simply, I will use a quote from Hod Lipson from ASME.org (Lipson is the author of  Fabricated: The New World of 3D Printing): “Unlike traditional 3D printing of plastics and metal where after you finish printing you have your part, with bioprinting it’s just the beginning. Even after you finish printing there is a long road ahead. You have to incubate the part, simulate its environment – it’s much more complicated.”

This month I was lucky enough to hear David Kolesky from Harvard University’s Wyss Institute discuss his team’s latest work on 3D bioprinting. The idea that we are beginning to be able to print human tissue is mind-blowing, and to hear details from someone in the forefront of this work was awe-inspiring.

Human Tissue Engineering: Challenges and Solutions
David Kolesky is part of a team at Jennifer Lewis' Research Group at the Harvard John A. Paulson School for Engineering and Applied Sciences (SEAS) and the Wyss Institute for Biologically Inspired Engineering at Harvard University who is working on engineering human tissue. In his talk at Biotech Week Boston on October 6, Kolesky focused on the team's work with engineering kidney tissue in particular. He described his team’s focus and some of their challenges: “(A human) kidney has a million nephrons, within the nephron we’re focused on the proximal tubule” and “(human) tissue is extremely difficult to mimic, because (of its) hierarchical structures that have a composite nature.” (You can see the tubule below, courtesy Wyss Institute.)


Stem-Cell Laden ‘Ink’ Becomes Living Tissue
Kolesky told the story of exactly how he was using 3D printing, specifically “bioprinting” to solve the challenges of vascularization. To someone not well versed in the latest discoveries it was fairly astounding – especially when he elucidated the use of “stem-cell laden ‘ink’ to build fully vascularized human tissue”. The materials they’re using are almost as fascinating at the engineered tissue: a hydrogel, which becomes “liquid when cooled” is the substance Kolesky and the Wyss Institute is using to make the bioprinting happen. With the methods he’s using, they are able to “keep these vascular networks perfusable for up to 45 days”. Their 3D printed proximal tubules actually contain living human cells and mimic many biological functions of nephrons.

How do they do that? Once the tubules are printed, they pump living kidney cells into them. After several days in the tubules the cells begin to function like the ones in our bodies. Cells in the tubules are “trained” by the chemistry of their environment to become and behave exactly like native kidney cells.

Researchers Can Now Study Real-Time Damage To Tubules
There are 60,000 people on a national waiting list for kidneys, and the CDC says that 1 in 10 American adults, more than 20 million people, have some level of chronic kidney disease. There is an urgent need for science to advance this research. The Wyss Institute is not only at the forefront of bringing us closer being able to engineer human kidneys in the future; with the current research researchers will actually be able to induce damage on these bioengineered tubules as if they were the real thing to study effects of drugs or toxins.

We Want a Synergistic Relationship with Biology
Kolesky closed his talk with the quote: ”We want a synergistic relationship with biology.” In fact Wyss Institute's Mission Statement is: "The Wyss Institute seeks to transform engineering, medicine and the environment by creating new materials and devices using Nature’s design principles".

Their team's paper:”Bioprinting of 3D Convoluted Renal Proximal Tubules on Perfusable Chips” was published in Nature Scientific Reports several days after Biotech Week Boston and gives more detail on Kolesky’s research. You can read the paper here.

Interested in hearing more about innovations in the intersection of bioengineering and medicine? Download our report here. And don't forget to follow Biotech Week Boston on Twitter for news on innovation in biotech and medicine. Each year passionate scientists and innovators converge on Boston to share ground breaking data, research and ideas - don't miss our next event in September 2017!





Share this article with your social network, just click below to share now!


Thursday, October 20, 2016

FDA/CMS: New Administration, New Challenges?

Knect365 FDA/CMS Summit, photo on-site
photo credit: @KimTweetsDC

For over 20 years we have been working hard on delivering you with first-hand insights into one of the most heavily-regulated industries in the world.

With recent debates over drug pricing, the FDA is faced with some challenges over regulation policies to ensure the healthy balance of big pharma companies on the market.


Here are the main three questions that are bugging the minds of the Top Biopharma Executives today:


• What does the future hold for the Affordable Care Act and health reform in the post-Obama landscape?
• What is the state of biosimilars in the US, and how these medicines may impact the cost curve for biologics as more reach the market and uptake becomes measurable?
[read an excerpt from the panel discussion with experts from Mylan, Pfizer and Momenta Pharmaceuticals “Biosimilars are here. Now what?”.]
• Transparency around pricing.

Do these topics keep you up all night as well?

Be the first one to learn the updates directly from CDER and CMS right in the heart of DC, the political epicenter of the United States at the 11th Annual FDA/CMS Summit.


Some of the themes to be discussed at the Summit include:


• An overview of regulatory and policy news;
• Regulatory & reimbursement expertise from KaloBios Pharmaceuticals Inc., FDA, REGENXBIO, Aimed Alliance, Acorda Therapeutics, Beth Israel Deaconess Medical Center, and many others;
• The state of biosimilars and revisions to BSUFA;
• Drug Development Innovation including regulatory strategies of pandemics such as Ebola and Zika.

For the full range of topics download the brochure here.

Join an open dialog over the industry issues with other health care professionals from the FDA and CMS regulatory agencies, including Janet Woodcok, Gerald Dal Pan and John Jenkins at the FDA/CMS Summit, this December, 14 – 15th in Washington, DC.

As a valued member of our community you can register with a special discount of $100 OFF the current rate using this code: PFDA16SOCIAL.

Secure your spot and the best rate here.



Stay tuned:



Share this article with your social network, just click below to share now!